NasdaqGM - Delayed Quote USD

Rani Therapeutics Holdings, Inc. (RANI)

0.5605
-0.0122
(-2.13%)
At close: June 12 at 4:00:00 PM EDT
0.5999
+0.04
+(7.03%)
After hours: June 12 at 5:51:43 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Mir A. Imran Executive Chairman 40k -- 1957
Mr. Talat Imran CEO & Director 105.82k -- 1982
Mr. Svai S. Sanford Chief Financial Officer 416k -- 1970
Dr. Mir Hashim Chief Scientific Officer 416k -- 1960
Mr. Alireza Javadi Vice President of Technical Operations -- -- --
Ms. Bella Vazquez Vice President of Human Resources -- -- --
Ms. Kate McKinley M.B.A. Chief Business Officer -- -- 1977

Rani Therapeutics Holdings, Inc.

2051 Ringwood Avenue
San Jose, CA 95131
United States
408 457 3700 https://www.ranitherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
105

Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Corporate Governance

Rani Therapeutics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 13, 2025 at 8:05 PM UTC

Rani Therapeutics Holdings, Inc. Earnings Date

Recent Events

May 29, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 20, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 13, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 6, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 30, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

April 16, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

April 9, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 31, 2025 at 12:00 AM UTC

S-8: Offering Registrations

November 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

September 11, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers